Sec. 2-110. Commission on Innovation and Productivity. Membership. Duties.
Sec. 2-111. Results First Policy Oversight Committee.
Secs. 2-112 to 2-118. Reserved
Sec. 2-119. Chronic kidney disease advisory committee.
Sec. 2-110. Commission on Innovation and Productivity. Membership. Duties. Section 2-110 is repealed, effective July 1, 2013.
(P.A. 93-351, S. 1, 3; P.A. 96-251, S. 2; P.A. 13-299, S. 95.)
| (Return to Chapter Table of Contents) |
(Return to List of Chapters) |
(Return to List of Titles) |
Sec. 2-111. Results First Policy Oversight Committee. (a) There is established a Results First Policy Oversight Committee. The committee shall advise on the development and implementation of the Pew-MacArthur Results First cost-benefit analysis model, with the overall goal of promoting cost effective policies and programming by the state.
(b) The committee shall consist of the following members:
(1) Four members of the General Assembly, one of whom shall be appointed by the speaker of the House of Representatives, one of whom shall be appointed by the president pro tempore of the Senate, one of whom shall be appointed by the minority leader of the House of Representatives, and one of who shall be appointed by the minority leader of the Senate;
(2) The Chief Court Administrator, or the Chief Court Administrator's designee;
(3) The Comptroller, or the Comptroller's designee;
(4) The director of the Office of Fiscal Analysis;
(5) The director of the Office of Legislative Research;
(6) The director of the Institute for Municipal and Regional Policy at The University of Connecticut;
(7) The executive director of the Commission on Women, Children, Seniors, Equity and Opportunity, or a designee;
(8) A representative of private higher education, appointed by the Connecticut Conference of Independent Colleges;
(9) Two representatives of the Connecticut business community, one of whom shall be appointed by the majority leader of the House of Representatives, and one who shall be appointed by the majority leader of the Senate; and
(10) Such other members as the committee may prescribe.
(c) All appointments to the committee under subdivisions (1) to (10), inclusive, of subsection (b) of this section shall be made not later than thirty days after June 19, 2013. Any vacancy shall be filled by the appointing authority.
(d) A member of the General Assembly selected jointly by the speaker of the House of Representatives and the president pro tempore of the Senate shall be the chairperson of the committee. Such chairperson shall schedule the first meeting of the committee, which shall be held not later than sixty days after June 19, 2013.
(e) Members of the committee shall serve without compensation, except for necessary expenses incurred in the performance of their duties.
(f) Not later than October 1, 2013, and annually thereafter, the committee shall submit a report to the Governor and the joint standing committee of the General Assembly having cognizance of matters relating to appropriations and the budgets of state agencies, in accordance with section 11-4a, recommending measures to implement the Pew-MacArthur Results First cost-benefit analysis model.
(P.A. 13-247, S. 42; May Sp. Sess. P.A. 16-3, S. 133; P.A. 17-60, S. 7; P.A. 19-117, S. 108; June Sp. Sess. P.A. 21-2, S. 23.)
History: P.A. 13-247 effective June 19, 2013; May Sp. Sess. P.A. 16-3 amended Subsec. (b)(8) to replace “executive director of the Commission on Children” with “executive director of the Commission on Women, Children and Seniors or a designee”, effective July 1, 2016; P.A. 17-60 amended Subsec. (b) to delete Subdiv. (5) re director of Office of Program Review and Investigations and redesignate Subdivs. (6) to (11) as Subdivs. (5) to (10) and amended Subsec. (c) to make a conforming change, effective July 1, 2017; P.A. 19-117 amended Subsec. (b)(7) by replacing “Commission on Women, Children and Seniors” with “Commission on Women, Children, Seniors, Equity and Opportunity”, effective July 1, 2019; June Sp. Sess. P.A. 21-2 amended Subsec. (b)(6) by replacing “Central Connecticut State University” with “The University of Connecticut”.
| (Return to Chapter Table of Contents) |
(Return to List of Chapters) |
(Return to List of Titles) |
Secs. 2-112 to 2-118. Reserved for future use.
Sec. 2-119. Chronic kidney disease advisory committee. (a) There is established a chronic kidney disease advisory committee. The advisory committee shall:
(1) Work directly with policymakers, public health organizations and educational institutions to:
(A) Increase awareness of chronic kidney disease in this state; and
(B) Develop health education programs that:
(i) Are intended to reduce the burden of kidney disease throughout this state;
(ii) Include an ongoing health and wellness campaign that is based on relevant research;
(iii) Promote preventive screenings; and
(iv) Are promoted through social media and public relations campaigns;
(2) Examine chronic kidney disease, kidney transplantation, including, but not limited to, kidney transplantation as a preferred treatment for chronic kidney disease, living and deceased kidney donation and racial disparities in the rates of individuals afflicted with chronic kidney disease;
(3) Examine methods to reduce the occurrence of chronic kidney disease by controlling the most common risk factors, diabetes and hypertension, through early detection and preventive efforts at the community level and disease management efforts in the primary care setting;
(4) Identify the barriers to the adoption of best practices and the policies available to address such barriers;
(5) Develop an equitable, sustainable, cost-effective plan to raise awareness about the importance of early detection, screening, diagnosis and treatment of chronic kidney disease and prevention; and
(6) Examine the potential for an opt-out organ or kidney donor registry.
(b) The advisory committee shall consist of the following members:
(1) One appointed by the speaker of the House of Representatives, who shall represent the renal provider community;
(2) One appointed by the president pro tempore of the Senate, who shall represent a medical center with a kidney-related program;
(3) One appointed by the majority leader of the House of Representatives;
(4) One appointed by the majority leader of the Senate;
(5) One appointed by the minority leader of the House of Representatives;
(6) One appointed by the minority leader of the Senate;
(7) One appointed by the Governor;
(8) The Commissioner of Public Health, or the commissioner's designee;
(9) One appointed by the chief executive officer of the National Kidney Foundation;
(10) One appointed by the chief executive officer of the American Kidney Fund; and
(11) At least three additional members appointed by the chairpersons of the joint standing committee of the General Assembly having cognizance of matters relating to public health, one of whom shall represent the kidney physician community, one of whom shall represent a nonprofit organ procurement organization, one of whom shall represent the kidney patient community in this state and such other members that such chairpersons, in their discretion, agree are necessary to represent public health clinics, community health centers, minority health organizations and health insurers.
(c) Any member of the advisory committee appointed under subdivision (1), (2), (3), (4), (5), (6) or (11) of subsection (b) of this section may be a member of the General Assembly.
(d) All initial appointments to the advisory committee shall be made not later than thirty days after May 23, 2022. Any vacancy shall be filled by the appointing authority.
(e) The speaker of the House of Representatives and the president pro tempore of the Senate shall select the chairpersons of the advisory committee from among the members of the advisory committee. Such chairpersons shall schedule the first meeting of the advisory committee, which shall be held not later than sixty days after May 23, 2022. Meetings of the advisory committee may, at the discretion of the chairpersons of the advisory committee, be conducted on a virtual platform.
(f) The administrative staff of the advisory committee shall be selected by the Office of Legislative Management in consultation with the chairpersons of the advisory committee.
(g) Not later than January 1, 2024, and annually thereafter, the advisory committee shall submit a report on its findings and recommendations to the joint standing committee of the General Assembly having cognizance of matters relating to public health in accordance with the provisions of section 11-4a.
(P.A. 21-156, S. 4; P.A. 22-58, S. 49.)
History: P.A. 21-156 effective July 12, 2021; P.A. 22-58 amended Subsec. (b) by deleting Subdivs. (1) to (5), redesignating existing Subdivs. (6) to (16) as Subdivs. (1) to (11), amended Subsec. (c) by deleting references to Subdivs. (7) to (10) and (16) and making a conforming change, amended Subsecs. (d) and (e) by replacing “July 12, 2021” with “May 23, 2022”, amended Subsec. (g) by replacing “2022” with “2024”, effective May 23, 2022.
| (Return to Chapter Table of Contents) |
(Return to List of Chapters) |
(Return to List of Titles) |